Meridian Bioscience predicts strong revenue from diagnostic sales; Switch from Windows to Linux to reduce med device hackability;

 @FierceMedDev: Moving on from the Duet recall, Covidien gets a 510(k) for its next-gen surgical stapler. News | Follow @FierceMedDev

 @MarkHFierce: Stent use can help certain patients more than medical therapy if used on the early side. Release | Follow @MarkHFierce

 @DamianFierce: Joining other big shots in the device game, Medtronic has opened an R&D center in China. Report | Follow @DamianFierce

> Meridian Bioscience ($VIVO) is predicting a strong fiscal 2013, planning to notch between $190 million to $195 million on the strength of new diagnostic kits. Article

> Amid all the concern over the hackability of networked medical devices, one tech blogger suggests switching from Windows to Linux could boost software security. Story

> A new heart separation device improved three-year outcomes in heart failure patients. Release

> In Kenya, AIDS-prevention groups are lobbying the government to approve two minimally-invasive circumcision devices, citing study results saying circumcised men reduced risk of HIV infection by 65%. News

> The worldwide market for cancer diagnostics will explode over the next decade, according to a new study from ReportsnReports. More

>  A new device that mechanically removed stroke-causing clots from blocked brain arteries performed well in a recent clinical trial. Item

Biotech News

 @FierceBiotech: Special report: The Alzheimer's pipeline... What's next? Report | Follow @FierceBiotech

 @JohnCFierce: Resverlogix touts positive PhIIb atherosclerosis data, sets sights on PhIII deal. More | Follow @JohnCFierce

 @RyanMFierce: What changes will Roche vet Pascal Soriot make as CEO of AstraZeneca? More | Follow @RyanMFierce

> Alnylam reaps $29M harvest in new ag bio deal with Monsanto. News

> Analysis: Where will Pascal Soriot take AstraZeneca now? More

> FDA OK for HIV pill Quad sets up potential confrontation over Gilead's price. Article

Pharma News

 @FiercePharma: AstraZeneca's gain is Roche's loss: Stock down 1% after $AZN woos away Pascal Soriot for CEO job. More | Follow @FiercePharma

> Forest adopts 'poison pill' to fend off Icahn. Report

> AstraZeneca entices Roche exec to take on CEO challenge. News

> Gilead draws early fire for new HIV med's $28K price. Story

Biotech Research News

> Acorda's drug treats nerve damage-related ED in preclinical test. Article

> Novira raises $23M for hepatitis B/HIV drug work. News

> Genentech, U. Minnesota scientists discover new colon cancer red flags. Story

> Johns Hopkins team turning blood cells into stem cells. More

> Melanoma stem cells may carry provocative drug target. Item

Pharma Manufacturing News

> Drugmaker EirGen thinks plan to put waste station nearby stinks. More

> Sun says FDA clears plants where Marshalls seized products in 2009. News

> CSL, whose vaccine was tied to convulsions, gets FDA closeout letter. Story

> Hospira commits to 200 jobs, $85M investment, at troubled plant. Report

Suggested Articles

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.